Saturday 17 October 2026
Export ANEB’s income statement to Excel — free account
Anebulo Pharmaceuticals, Inc.
ANEB Healthcare Biotechnology
In the quarter to December 2025, EPS grew 44.4% and free cash flow grew 6.58%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.00
0.31
−100.00%
Follow ANEB
| Older periods | Mar '25 | Jun '25 | Sep '25 | Dec '25 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(83.37%) | (109.69%) | (145.11%) | (69.69%) | |
| (76.88%) | (104.63%) | (128.22%) | (63.17%) | ||
ROIC |
(2,817.98%) | (19,215.63%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(57.98%) | (73.94%) | (88.20%) | (102.45%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.16) | (0.19) | (0.14) | (0.14) | |
Free Cash Flow |
(6.75) | (6.35) | (5.93) | (5.84) | |
| Other line items | |||||
Cash ROIC |
(25.24%) | (27.27%) | (29.53%) | (34.40%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(19.40) | (24.15) | (26.70) | (30.61) | |
Operating CF/Net income |
0.88 | 0.75 | 0.70 | 0.73 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.16) | (0.19) | (0.14) | (0.14) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates